Evidence map›Paper›PMID 23379366›Full record

ReviewMolecular pharmaceutics2013

Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo.

Jin-Woo Kim, Ekaterina I Galanzha, David A Zaharoff, Robert J Griffin, Vladimir P Zharov

Abstract readReview
In one paragraph

Review in Molecular pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Nanotools for Sepsis Diagnosis and Treatment.Advanced healthcare materials · 2021
    Review
  8. Review
  9. Towards Reaching the Total Blood Volume by in vivo Flow Cytometry and Theranostics.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2019
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Targeting tumor metastases: Drug delivery mechanisms and technologies.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jin-Woo KimBio/Nano Technology Laboratory, Institute for Nanoscience and Engineering, University of Arkansas, Fayetteville, Arkansas 72701, USA. jwkim@uark.edu
Ekaterina I Galanzha
David A Zaharoff
Robert J Griffin
Vladimir P Zharov

Funding

PHYSIOLOGICAL FACTORS IN HYPERTHERMIAR01CA044114 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI GRIFFIN, ROBERT JAMES · 1987 to 2012
$3.3M
In vivo real-time detection of circulating melanoma cellsR01CA131164 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI SUEN, JAMES · 2009 to 2019
$3.1M
Photoswitchable nanoprobes for in vivo flow cytometryR01EB017217 · NIBIB · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAROV, VLADIMIR P · 2014 to 2017
$1.3M
Multifunctional nanotubes for in vivo detecting/purging circulating cancer cellsR01EB009230 · NIBIB · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAROV, VLADIMIR P · 2009 to 2012
$1.2M
Photothermal Imaging of Live CellsR01EB000873 · NIBIB · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAROV, VLADIMIR P · 2005 to 2008
$1.1M
Chitosan-based Delivery and Immunopotentiation of Cancer VaccinesK22CA131567 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI ZAHAROFF, DAVID · 2010 to 2012
$505k
Integrated Photothermal NanoprobesR21EB005123 · NIBIB · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAROV, VLADIMIR P · 2006 to 2007
$332k
In vivo molecular laser detection and treatment of circulating cancer stem cellsR21CA139373 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAROV, VLADIMIR P · 2009 to 2010
$329k
Photothermal Evaluation of Drug Toxicity at Cell LevelR21CA097422 · NCI · UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK · PI ZHAROV, VLADIMIR P · 2003 to 2004
$272k
NCI NIH HHS K22 CA131567NCI NIH HHS K22CA131567NCI NIH HHS R01 CA044114NCI NIH HHS R01 CA131164NCI NIH HHS R01CA131164NCI NIH HHS R01CA44114NCI NIH HHS R21 CA097422NCI NIH HHS R21 CA139373NCI NIH HHS R21CA139373NIBIB NIH HHS R01 EB000873NIBIB NIH HHS R01EB000873NIBIB NIH HHS R01 EB009230NIBIB NIH HHS R01EB009230NIBIB NIH HHS R01 EB017217NIBIB NIH HHS R21 EB005123
6 · The paper itself

Abstract

Many life-threatening diseases are disseminated through biological fluids, such as blood, lymph, and cerebrospinal fluid. The migration of tumor cells through the vascular circulation is a mandatory step in metastasis, which is responsible for ∼90% of cancer-associated mortality. Circulating pathogenic bacteria, viruses, or blood clots lead to other serious conditions including bacteremia, sepsis, viremia, infarction, and stroke. Therefore, technologies capable of detecting circulating tumor cells (CTCs), circulating bacterial cells (CBCs), circulating endothelial cells (CECs), circulating blood clots, cancer biomarkers such as microparticles and exosomes, which contain important microRNA signatures, and other abnormal features such as malaria parasites in biological fluids may facilitate early diagnosis and treatment of metastatic cancers, infections, and adverse cardiovascular events. Unfortunately, even in a disease setting, circulating abnormal cells are rare events that are easily obscured by the overwhelming background material in whole blood. Existing detection methods mostly rely on ex vivo analyses of limited volumes (a few milliliters) of blood samples. These small volumes limit the probability of detecting CTCs, CECs, CBCs and other rare phenomena. In vivo detection platforms capable of continuously monitoring the entire blood volume may substantially increase the probability of detecting circulating abnormal cells and, in particular, increase the opportunity to identify exceedingly rare and potentially dangerous subsets of these cells, such as circulating cancer stem cells (CCSCs). In addition, in vivo detection technologies capable of destroying and/or capturing circulating abnormal cells may inhibit disease progression. This review focuses on novel therapeutic and diagnostic (theranostic) platforms integrating in vivo real-time early diagnosis and nano-bubble based targeted therapy of CTCs, CECs, CBCs and other abnormal objects in circulation. This critical review particularly focuses on nanotechnology-based theranostic (nanotheranostic) approaches, especially in vivo photoacoustic (PA) and photothermal (PT) nanotheranostic platforms. We emphasize an urgent need for in vivo platforms composed of multifunctional contrast nanoagents, which utilize diverse modalities to realize a breakthrough for early detection and treatment of harmful diseases disseminated through the circulation.

Indexed as

HumansMolecular ImagingNanotechnologyNeoplastic Cells, CirculatingPhotoacoustic Techniques

Identifiers

PMID23379366
PMCPMC3752784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.